Designing an Implementation Strategy for Lung Screening and Smoking Cessation Treatment in Community Health Centers

Smoking Cessation Clinical Trial

— SAILS-FQHC  

Official title:

A Systematic Approach to Designing an Implementation Strategy to Increase Lung Cancer Screening and Smoking Cessation Treatment Among Federally Qualified Community Health Center Patients Who Smoke

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05447897
• Other study ID #: 22-215
• Secondary ID: P50CA244433-03S3
• Status: Completed
• Phase: N/A
• Start date: December 1, 2022
• Est. completion date: May 31, 2023

Study information

• Verified date: March 2024
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tobacco use is the leading preventable cause of death in the US and a major driver of health disparities. Among our tools for reducing the harms of tobacco is lung cancer screening (LCS). This study will combine a review of existing qualitative and quantitative data on barriers to lung cancer screening and smoking cessation in underserved populations, a quantitative analysis of predictors of lung cancer screening and smoking cessation treatment use among Massachusetts Federally Qualified Health Centers (FQHC)s, and a stakeholder advisory group to synthesize these data and select implementation strategies that reflects the critical determinants and the strengths and resource constraints of the Federally Qualified Health Centers (FQHC) context.

Description:

Aim 1) To design an implementation strategy that targets critical components in the delivery of SCT or LCS services for patients who smoke.

Aim 2) To assess the acceptability, appropriateness and feasibility of the implementation strategy among community health center staff.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: May 31, 2023
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

FQHC implementation team including staff in the intervention FQHCs and their lung screening partners

Exclusion Criteria:

FQHC staff or partners who leave the organization before end of study

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Other:
• Qualitative Group Interviews
One time interview, 60-90 minutes
• Stakeholder advisory group
The team will meet with the stakeholder advisory group four times for 1-2 hours each

Locations

Country	Name	City	State
United States	Massacusetts General Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of Intervention Measure	Feasibility of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes	End of study, up to 16 weeks
Secondary	Acceptability of Intervention Measure	Acceptability of Intervention Measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes	End of study, up to 16 weeks
Secondary	Intervention Appropriateness Measure	Intervention appropriateness measure, 5-point Likert scales (range 1-5), higher values reflect favorable outcomes	End of study, up to 16 weeks